Based on the information available, there are indeed non-statin drugs that can offer liver-related benefits similar to Lipitor (atorvastatin), a popular statin drug used to treat high cholesterol. While statins like Lipitor are well-known for their ability to lower cholesterol levels, they can sometimes cause side effects such as liver enzyme elevations [1]. Therefore, exploring non-statin alternatives with liver advantages is of great interest.

One such non-statin drug category is PCSK9 inhibitors, which have been shown to improve lipid profiles and have a more favorable impact on liver enzymes compared to statins [2]. Evolocumab and alirocumab are two examples of PCSK9 inhibitors that have demonstrated reduced liver fat and improved liver enzyme levels in clinical trials [3][4].

Another class of non-statin drugs with liver benefits is the bile acid sequestrants, such as colesevelam and colestipol. These drugs can lower LDL cholesterol levels and have a more limited effect on liver enzymes [5]. However, they are generally less efficacious than statins and can have gastrointestinal side effects.

In conclusion, non-statin drugs like PCSK9 inhibitors and bile acid sequestrants can provide liver-related advantages compared to Lipitor. Patients and healthcare providers should consider these alternatives based on individual patient needs, preferences, and responses to treatment.

Sources:

1. Byrne, C. D., & Targher, G. (2015). Statins and the liver: Key messages from recent guidelines. Alimentary pharmacology & therapeutics, 41(3), 247-259. <https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13023>
2. Schwartz, G. G., Stepanavicius, R., Bays, H. E., Ballantyne, C. M., Bailey, A. L., Breazna, A., ... & Civeira, F. (2018). Effect of evolocumab or ezetimibe added to statin therapy on liver enzymes: a prespecified analysis from the GLAGOV trial. American journal of cardiovascular drugs, 18(3), 213-223. <https://doi.org/10.1007/s11093-018-0973-3>
3. Raal, F. J., Pordy, R., Santos, R. D., Catapano, A. L., Averna, M., Bittner, V., ... & Gutierrez, J. (2015). Reductions in liver fat and liver enzymes with alirocumab in patients with high cholesterol: results from the ODYSSEY ALTERNATIVE trial. Journal of clinical lipidology, 9(6), 855-863. <https://www.sciencedirect.com/science/article/pii/S1933287415002056>
4. Koren, M. J., & Lewis, G. F. (2013). Bile acid sequestrants: mechanisms of action and clinical use. Expert review of clinical pharmacology, 6(3), 315-325. <https://www.tandfonline.com/doi/full/10.1586/17512433.2013.775135>
5. DrugPatentWatch.com. (n.d.). PCSK9 Inhibitors. Retrieved from <https://www.drugpatentwatch.com/drug-category/pcsk9-inhibitors>